Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of Neurotoxicity
- 19 November 1999
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 265 (2), 479-483
- https://doi.org/10.1006/bbrc.1999.1693
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAILThe Journal of Experimental Medicine, 1999
- Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivoNature Medicine, 1999
- Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analysesInternational Journal of Cancer, 1998
- Death Receptors: Signaling and ModulationScience, 1998
- APO2 ligand: a novel lethal weapon against malignant glioma?FEBS Letters, 1998
- CD95 Ligand: Lethal Weapon Against Malignant Glioma?Brain Pathology, 1998
- Interleukin 1β-converting Enzyme Related Proteases/Caspases Are Involved in TRAIL-induced Apoptosis of Myeloma and Leukemia CellsThe Journal of cell biology, 1997
- Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeuticsCancer Immunology, Immunotherapy, 1997
- Lethal effect of the anti-Fas antibody in miceNature, 1993